Article

July 18, 2013

Dr. Jan Berger Discusses the Triple Aim and the Role of Retail Pharmacy

Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, and editor-in-chief of The American Journal of Pharmacy Benefits, says the triple aim consists of cost, quality, and access. Additionally, the largest benefit that healthcare consumers can use is their health pharmacy benefit.

Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, and editor-in-chief of The American Journal of Pharmacy Benefits, says the triple aim consists of cost, quality, and access. Additionally, the largest benefit that healthcare consumers can use is their health pharmacy benefit.

“Utilizing the retail pharmacies as a point of access really can help address many of the factors in a triple aim,” Berger says.

Related Videos

Scott Manaker,MD

Juan Carlos Martinez, MD

Parth Rali, MD

IMS Recap

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel

April Armstrong, MD, MPH, chief of dermatology, UCLA

Javed Butler, MD, MPH, MBA

Screenshot during an interview with Aaron Adkisson, PharmD

Kirollos Hanna, PharmD

Related Content

Breastcancergeneticrisk | Image Credit: © Rasi-stock.adobe.com

October 7th 2024

Managing Germline Mutations in Hereditary Breast Cancer Risk

Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.

Sustaining Compassionate Trauma Care Across Communities

September 30th 2024

Sustaining Compassionate Trauma Care Across Communities

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.

Surbhi Sidana, MD

October 3rd 2024

What the Approval of Isatuximab Plus VRd Adds to Multiple Myeloma Care

Hayden E. Klein Maggie L. Shaw

Surbhi Sidana, MD, MBBS, shares how the addition of an anti-CD38 antibody to the VRd regimen significantly improves progression-free survival for patients with transplant-ineligible multiple myeloma.

Managed Care Cast

September 27th 2024

Frameworks for Advancing Health Equity: Community Wellness Centers

Giuliana Grossi

Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.

Surbhi Sidana, MD, MBBS, Stanford University

October 2nd 2024

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant.

Q&A With Varsha Srivatsan, MSci, O’Neill Institute for National and Global Health Law

October 2nd 2024

From Criminalization to Compassion: The Evolution of HIV Laws

The 25th International AIDS Conference took place July 22-26 in Munich, Germany, and one of the sessions delved into the potential impact of civil society laws on the 95-95-95 targets as laid out in the UNAIDS Global AIDS Strategy for 2021 to 2026.

Related Content

Breastcancergeneticrisk | Image Credit: © Rasi-stock.adobe.com

October 7th 2024

Managing Germline Mutations in Hereditary Breast Cancer Risk

Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.

Sustaining Compassionate Trauma Care Across Communities

September 30th 2024

Sustaining Compassionate Trauma Care Across Communities

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.

Surbhi Sidana, MD

October 3rd 2024

What the Approval of Isatuximab Plus VRd Adds to Multiple Myeloma Care

Hayden E. Klein Maggie L. Shaw

Surbhi Sidana, MD, MBBS, shares how the addition of an anti-CD38 antibody to the VRd regimen significantly improves progression-free survival for patients with transplant-ineligible multiple myeloma.

Managed Care Cast

September 27th 2024

Frameworks for Advancing Health Equity: Community Wellness Centers

Giuliana Grossi

Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.

Surbhi Sidana, MD, MBBS, Stanford University

October 2nd 2024

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant.

Q&A With Varsha Srivatsan, MSci, O’Neill Institute for National and Global Health Law

October 2nd 2024

From Criminalization to Compassion: The Evolution of HIV Laws

The 25th International AIDS Conference took place July 22-26 in Munich, Germany, and one of the sessions delved into the potential impact of civil society laws on the 95-95-95 targets as laid out in the UNAIDS Global AIDS Strategy for 2021 to 2026.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions